{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:23:42Z","timestamp":1783171422482,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["BJCH2024CZ02"],"award-info":[{"award-number":["BJCH2024CZ02"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z250010"],"award-info":[{"award-number":["Z250010"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["A002863"],"award-info":[{"award-number":["A002863"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92359203"],"award-info":[{"award-number":["92359203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmcl.2026.130682","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:18:45Z","timestamp":1778563125000},"page":"130682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer"],"prefix":"10.1016","volume":"138","author":[{"given":"Siqi","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soontaree","family":"Sriwongta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opa","family":"Vajragupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornchai","family":"Rojsitthisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2026.130682_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10449","key":"10.1016\/j.bmcl.2026.130682_bb0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130682_bb0015","first-page":"145","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130682_bb0020","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/14796694.2024.2352276","article-title":"STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer","volume":"20","author":"Saeed","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.bmcl.2026.130682_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1723546","article-title":"Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies","volume":"15","author":"Tang","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130682_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130682_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","article-title":"Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025)","volume":"18","author":"Huang","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130682_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130682_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104135","article-title":"Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study","volume":"10","author":"Antoniotti","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130682_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-024-01970-8","article-title":"An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer","volume":"23","author":"Levy","year":"2024","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130682_bb0055","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.21873\/anticanres.17179","article-title":"Identification of DNA repair-related genes as biomarkers reflecting MSI, TMB, and TIL in colorectal Cancer","volume":"44","author":"Fukuda","year":"2024","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130682_bb0060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054757","article-title":"Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes","volume":"11","author":"Kim","year":"2022","journal-title":"Oncoimmunology"},{"issue":"8094","key":"10.1016\/j.bmcl.2026.130682_bb0065","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41586-025-09679-4","article-title":"Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers","volume":"648","author":"Tan","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130682_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130682_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146707","article-title":"Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function","volume":"6","author":"Petty","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.bmcl.2026.130682_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101234","article-title":"PD-L1(+) tumor-associated macrophages induce CD8(+) T cell exhaustion in hepatocellular carcinoma","volume":"69","author":"Nosaka","year":"2025","journal-title":"Neoplasia"},{"issue":"43","key":"10.1016\/j.bmcl.2026.130682_bb0085","doi-asserted-by":"crossref","first-page":"E10119","DOI":"10.1073\/pnas.1802166115","article-title":"Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)","volume":"115","author":"Kowanetz","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130682_bb0090","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.bmcl.2026.130682_bb0095","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-22-3699","article-title":"FDA approval summary: Atezolizumab as adjuvant treatment following surgical resection and platinum-based chemotherapy for stage II to IIIA NSCLC","volume":"29","author":"Mathieu","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130682_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002025","article-title":"Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues","volume":"9","author":"Kelly","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130682_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/biom10101388","article-title":"Anti-human PD-L1 Nanobody for Immuno-PET imaging: validation of a conjugation strategy for clinical translation","volume":"10","author":"Bridoux","year":"2020","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130682_bb0110","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/j.cllc.2025.08.013","article-title":"DISCERN: a randomized pilot study comparing dual versus single immune checkpoint blockade plus chemotherapy in PD-L1 negative advanced non-small cell lung Cancer","volume":"26","author":"Desai","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130682_bb0115","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem Rev"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130682_bb0120","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130682_bb0125","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/cancers15102708","article-title":"[89Zr]-Atezolizumab-PET imaging reveals longitudinal alterations in PDL1 during therapy in TNBC preclinical models","volume":"15","author":"Massicano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2026.130682_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109001","article-title":"Investigating the fate of Zirconium-89 labelled antibody in cynomolgus macaques","volume":"144-145","author":"Sasaki","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.bmcl.2026.130682_bb0135","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhao L, Lin X, et al. Comparison of tumor non-specific and PD-L1 specific imaging by near-infrared fluorescence\/Cerenkov luminescence dual-modality in-situ imaging. Mol Imaging, 23, 15353508241261473. Doi: https:\/\/doi.org\/10.1177\/15353508241261473.","DOI":"10.1177\/15353508241261473"},{"key":"10.1016\/j.bmcl.2026.130682_bb0140","article-title":"Evaluation of 68Ga-FAPI PET\/CT and 18F-FDG PET\/CT for the diagnosis of recurrent colorectal cancers","volume":"49","author":"Xi","year":"2024","journal-title":"Clini Transl Radiation Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130682_bb0145","first-page":"127","article-title":"Biodistribution and dosimetry of In-111\/Y-90-HuCC49\u0394Ch2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma","volume":"26","author":"Shen","year":"2011","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:03:43Z","timestamp":1783170223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0960894X26001496"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130682","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130682"}}